<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>MARKSANS</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">MARKSANS</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="marksans-pharma-limited" class="section level1">
<h1>Marksans Pharma Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MARKSANS.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MARKSANS.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MARKSANS.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MARKSANS.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MARKSANS.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MARKSANS.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MARKSANS.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MARKSANS.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MARKSANS.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-03 </em></p>
<div id="marksans-pharma-ltd.-marksans-analysis" class="section level3">
<h3>Marksans Pharma Ltd. (MARKSANS) Analysis</h3>
<p><strong>Overview of Recent Performance (Q2 &amp; H1 FY26):</strong> Marksans Pharma delivered a robust sequential recovery in Q2 FY26, with consolidated operating revenue of ₹720 cr (+12% YoY, +16% QoQ) and H1 revenue of ₹1,340 cr (+9% YoY). US/North America drove growth (53% of H1 revenue, +29% YoY), fueled by new launches and a $225-230M order book. EBITDA margin improved QoQ to 20.1% (H1: 18.2%, down YoY due to employee costs from Goa acquisition). PAT was ₹99 cr in Q2 (+1% YoY) and ₹157 cr in H1. The company remains <strong>debt-free</strong> with ₹667 cr cash, strong ratings (CARE AA-/Stable), and recent USFDA clearance for Unit 2 (Goa). FY25 revenue was ₹2,623 cr (OTC: 79%), with ambitions for ₹3,000 cr soon and ₹5,000 cr in 5-7 years.</p>
<p>Below is a structured analysis of <strong>headwinds</strong>, <strong>tailwinds</strong>, <strong>growth prospects</strong>, and <strong>key risks</strong>, derived from the earnings transcript, investor presentation, financial results, and disclosures.</p>
<div id="tailwinds-positive-factors" class="section level6">
<h6><strong>Tailwinds (Positive Factors)</strong></h6>
<ul>
<li><strong>US Market Strength</strong>: Largest contributor (53% H1 revenue, +29% YoY). Robust order book ($225-230M), new launches (digestives, pain), low-single-digit Rx pricing erosion. Private label OTC leadership (top-4 player in a $2-3B market). Tariff clarity boosts sentiment.</li>
<li><strong>UK Stability &amp; Pipeline</strong>: Stable demand despite pricing pressure; 3 new MHRA approvals in Q2 (e.g., Metformin, Moxonidine). 160+ MAs; goal to double revenue in 5-7 years via high-margin, niche Rx (bottom-line accretive).</li>
<li><strong>Cash &amp; Balance Sheet</strong>: ₹667 cr cash (Sep’25), consistent ops cash flow (₹75 cr H1), no debt. Enables M&amp;A/expansion (e.g., 100% stake in Dubai sub).</li>
<li><strong>Manufacturing Edge</strong>: Low-cost India base (Goa Unit 1/2: 26B units p.a. capacity, Unit 2 at 30% util.). Recent USFDA zero-483 inspection. Scalable to support ₹4,000 cr revenue.</li>
<li><strong>OTC Focus</strong>: 79% FY25 revenue from OTC (21% CAGR FY17-25); aligns with $204B global OTC market (IQVIA).</li>
<li><strong>Ratings &amp; ESG</strong>: CARE AA- upgrade; ESG score 73/100.</li>
</ul>
</div>
<div id="headwinds-challenges" class="section level6">
<h6><strong>Headwinds (Challenges)</strong></h6>
<ul>
<li><strong>Pricing &amp; Margin Pressure</strong>: UK erosion persists (gross margin dip to 57.2% Q2 from 59.7% YoY). H1 EBITDA margin 18.2% (-318 bps YoY) due to higher employee costs (Goa ramp-up).</li>
<li><strong>Soft Q1 &amp; Seasonality</strong>: H1 growth muted at 9% YoY; Q1 impacted by tariffs, inventory normalization. Q1 historically weak (low season).</li>
<li><strong>Working Capital Strain</strong>: 150 days (vs. 125-130 norm) from tariff-driven inventory buildup (5-6 months stock); expected to normalize by Q1 FY27.</li>
<li><strong>Macro Uncertainties</strong>: Recent US tariff fears (now eased, no pharma tariffs); lingering inflation/recession risks diverted focus to diversification.</li>
<li><strong>RoW Stagnation</strong>: 4% H1 revenue, flat/low growth; prudent approach post ECL provisions.</li>
</ul>
</div>
<div id="growth-prospects" class="section level6">
<h6><strong>Growth Prospects</strong></h6>
<table>
<colgroup>
<col width="26%" />
<col width="28%" />
<col width="45%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Driver</strong></th>
<th><strong>Details</strong></th>
<th><strong>Timeline/Target</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Revenue</strong></td>
<td>US-led (aim $300M order book); UK doubling; Europe/Canada entry.</td>
<td>₹3,000 cr near-term; ₹5,000 cr (5-7 yrs). US to 75% mix possible.</td>
</tr>
<tr class="even">
<td><strong>Markets</strong></td>
<td>Europe (organic Germany FY26, M&amp;A in 4 countries); Canada launch. ANZ stable.</td>
<td>Europe revenues H2 FY26+; peak season Q3/Q4 FY26.</td>
</tr>
<tr class="odd">
<td><strong>Capacity</strong></td>
<td>Unit 2 ramp (near ₹500 cr run-rate); old Goa expansion (tablets 1.3B/month, 3x softgel). Teva land bank.</td>
<td>CAPEX ₹100 cr (2026); supports &gt;₹4,000 cr.</td>
</tr>
<tr class="even">
<td><strong>Pipeline</strong></td>
<td>100+ products; FY25: 58 US SKUs commercialized, 12 UK approvals. Focus: OTC (pain, cough/cold, digestives).</td>
<td>25+ ANDAs/MAs filed; niche/high-margin UK Rx.</td>
</tr>
<tr class="odd">
<td><strong>Inorganic</strong></td>
<td>Front-end M&amp;A in Europe; strong cash for calibrated buys.</td>
<td>FY26 deals eyed.</td>
</tr>
<tr class="even">
<td><strong>Margins</strong></td>
<td>Operating leverage from ramp-up; FY26 EBITDA 19-20%+ (Q3 similar to Q2).</td>
<td>Sustainable 20%+ with scale.</td>
</tr>
</tbody>
</table>
<p><strong>Overall Outlook</strong>: High-teens revenue CAGR feasible; OTC tailwinds, diversification de-risk US reliance.</p>
</div>
<div id="key-risks" class="section level6">
<h6><strong>Key Risks</strong></h6>
<table>
<colgroup>
<col width="23%" />
<col width="40%" />
<col width="35%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Risk</strong></th>
<th><strong>Description</strong></th>
<th><strong>Mitigation</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Regulatory</strong></td>
<td>USFDA/MHRA inspections; delays in approvals.</td>
<td>Strong track record (recent zero-483); 2 USFDA-approved plants.</td>
</tr>
<tr class="even">
<td><strong>Tariffs/Geopolitical</strong></td>
<td>US policy shifts; inflation/recession.</td>
<td>Clarity emerged; diversification (Europe 10-15% potential).</td>
</tr>
<tr class="odd">
<td><strong>Pricing/Competition</strong></td>
<td>UK erosion; US private label rivalry (Perrigo et al.).</td>
<td>Niche products; low-cost India edge (15-20% cheaper est.).</td>
</tr>
<tr class="even">
<td><strong>Execution</strong></td>
<td>Capacity ramp; Europe organic delays; WC normalization.</td>
<td>Ample capacity headroom; cash buffer.</td>
</tr>
<tr class="odd">
<td><strong>Forex/Commodity</strong></td>
<td>Volatility (noted forex gains/losses).</td>
<td>Hedging; 2% R&amp;D spend.</td>
</tr>
<tr class="even">
<td><strong>M&amp;A Integration</strong></td>
<td>Overpay/acquisition risks (past success: Time-Cap 4x sales growth).</td>
<td>Disciplined (proven in UK/Aus/US).</td>
</tr>
</tbody>
</table>
<p><strong>Balanced Summary</strong>: Marksans is well-positioned for 15-20% growth, leveraging US momentum, UK pipeline, and Europe push amid stabilizing macros. Tailwinds (cash, capacity, OTC) outweigh headwinds (pricing, WC), but execution in new markets and tariff vigilance are critical. <strong>Buy/Hold</strong> for long-term compounding (target ₹3,000 cr FY27+); monitor Q3 peak season and Europe traction. Valuation: Attractive on 20-25x FY26 EPS (~₹8-9), given 20%+ margins and debt-free status. (Analysis based solely on provided docs; not investment advice.)</p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
